Monday, November 11, 2019
- 9:00AM-11:00AM
-
Abstract Number: 1662
Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?
Vasculitis – ANCA-Associated Poster II- 9:00AM-11:00AM
-
Abstract Number: 1551
Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1153
Double Trouble: Utility of Serial TB Screening in a Rheumatology Clinic Serving a Foreign-Born Population
Healthcare Disparities In Rheumatology Poster- 9:00AM-11:00AM
-
Abstract Number: 1687
Dramatic but Suspensive Effect of interleukin-1 Inhibitors on Persistent Urticarial Vasculitis
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides- 9:00AM-11:00AM
-
Abstract Number: 1555
Drug Survival and Safety of Biosimilar CT-P13 versus Reference Infliximab in Patients with Ankylosing Spondylitis: Data from the Korean College of Rheumatology Biologics Registry
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1548
Drug Survival of Secukinumab for Axial Spondyloarthritis in a Real-World Setting Possible Response Factors
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1511
Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1713
Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides- 9:00AM-11:00AM
-
Abstract Number: 1458
Dual Analysis with Nerve Ultrasound and Skin Biopsy in Painful Neuropathy Associated with Sjögren’s Syndrome
Sjögrenʼs Syndrome – Basic & Clinical Science Poster II- 9:00AM-11:00AM
-
Abstract Number: 1384
Duration of Oral Corticosteroid Therapy Does Not Change with the Addition of a Parenteral Injection: Results from a Real-World Canadian Early RA Cohort
RA – Treatments Poster II: Established Treatments- 9:00AM-11:00AM
-
Abstract Number: 1025
Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity
SLE – Etiology & Pathogenesis Poster I- 9:00AM-11:00AM
-
Abstract Number: 1066
Dysregulated IL-6 Dependent Dermal Adenosine Signaling via Adenosine A2A Receptor May Drive Fibrosis in Systemic Sclerosis
Systemic Sclerosis & Related Disorders – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 1349
Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada
RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures- 9:00AM-11:00AM
-
Abstract Number: 1541
Early Treatment Failure with Apremilast Among Biologic-naïve Patients with Psoriatic Arthritis